Growing into the future with gene editing

A field of molecular biology, gene editing is used to modify DNA building blocks in the genomes of humans, animals and plants in a targeted manner.

The pandemic has given a boost to a traditionally small and inward-looking sector - this in a diverse and increasingly digital, data-driven ecosystem of healthcare and biotech companies. It ranges from legacy giants like Pfizer to small, nimble disruptors.

Future-based companies

As a result of Pearson Henricks Inc. focus on future-based companies and innovations. Pearson Henricks Inc. has invested in companies such as CRISPR Therapeutics and Editas Medicine. There is a lot of growth going on at both companies.

As a leader in gene editing technology, CRISPR Therapeutics develops innovative gene-based medicines using its proprietary CRISPR/Cas9 platform. With CRISPR/Cas9 gene editing, genomic DNA can be edited with precision and directedness.

With a portfolio of therapeutic programs covering hemoglobinopathies, oncology, regenerative medicine, and rare diseases, CRISPR Therapeutics offers a broad range of therapeutic options. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.